LearnGlossaryMarketStocksSuperinvestorsSign in

GHRS

GH Research PLC

Healthcare · $1.6B market cap

Verdict

We can't put a fair value on GHRS right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-7.1% a year✗
Sales growth—?
Free cash flow growth—?
Return on invested capital-22.8%✗

Follow GHRS

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 8, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Schonharting Florian

director · 2026-09-08

Award

$58

About GH Research PLC

GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works